Abstract
Oestrogen receptor (ER) alpha is a well established prognostic marker in breast cancer, and all patients who are ER alpha positive receive tamoxifen as adjuvant endocrine therapy. Although ER alpha predicts a favourable disease outcome, the usefulness of ER beta as a clinical prognostic marker remains to be defined. Here, we outline the history of both ERs and discuss the implications ER beta has to patients with breast cancer.
Publication types
-
Historical Article
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Biomarkers, Tumor / history
-
Biomarkers, Tumor / metabolism*
-
Breast Neoplasms / diagnosis*
-
Breast Neoplasms / metabolism
-
Estrogen Receptor beta
-
Female
-
History, 19th Century
-
History, 20th Century
-
History, 21st Century
-
Humans
-
Immunohistochemistry
-
Prognosis
-
Protein Isoforms
-
Receptors, Estrogen / history
-
Receptors, Estrogen / metabolism*
-
Reverse Transcriptase Polymerase Chain Reaction
Substances
-
Biomarkers, Tumor
-
Estrogen Receptor beta
-
Protein Isoforms
-
Receptors, Estrogen